Cellectar Biosciences Inc (CLRB)
3.30
-0.03
(-0.90%)
USD |
NASDAQ |
May 17, 16:00
3.295
0.00 (0.00%)
After-Hours: 20:00
Cellectar Biosciences Enterprise Value: 95.35M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 95.35M |
| May 16, 2024 | 96.42M |
| May 15, 2024 | 97.50M |
| May 14, 2024 | 91.05M |
| May 13, 2024 | 86.74M |
| May 10, 2024 | 87.10M |
| May 09, 2024 | 93.20M |
| May 08, 2024 | 91.76M |
| May 07, 2024 | 94.99M |
| May 06, 2024 | 96.42M |
| May 03, 2024 | 99.65M |
| May 02, 2024 | 96.78M |
| May 01, 2024 | 90.33M |
| April 30, 2024 | 87.82M |
| April 29, 2024 | 88.18M |
| April 26, 2024 | 85.67M |
| April 25, 2024 | 85.31M |
| April 24, 2024 | 86.74M |
| April 23, 2024 | 80.19M |
| April 22, 2024 | 82.84M |
| April 19, 2024 | 77.54M |
| April 18, 2024 | 77.87M |
| April 17, 2024 | 83.51M |
| April 16, 2024 | 86.82M |
| April 15, 2024 | 87.15M |
| Date | Value |
|---|---|
| April 12, 2024 | 93.45M |
| April 11, 2024 | 100.09M |
| April 10, 2024 | 92.79M |
| April 09, 2024 | 100.75M |
| April 08, 2024 | 103.40M |
| April 05, 2024 | 101.75M |
| April 04, 2024 | 100.42M |
| April 03, 2024 | 109.04M |
| April 02, 2024 | 109.37M |
| April 01, 2024 | 107.05M |
| March 28, 2024 | 124.89M |
| March 27, 2024 | 113.76M |
| March 26, 2024 | 120.70M |
| March 25, 2024 | 121.34M |
| March 22, 2024 | 127.15M |
| March 21, 2024 | 121.34M |
| March 20, 2024 | 73.87M |
| March 19, 2024 | 74.91M |
| March 18, 2024 | 65.99M |
| March 15, 2024 | 68.68M |
| March 14, 2024 | 66.61M |
| March 13, 2024 | 69.93M |
| March 12, 2024 | 71.80M |
| March 11, 2024 | 74.70M |
| March 08, 2024 | 79.47M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-7.867M
Minimum
May 12 2022
127.15M
Maximum
Mar 22 2024
17.94M
Average
10.45M
Median
Apr 20 2022
Enterprise Value Benchmarks
| Perspective Therapeutics Inc | 817.27M |
| Eli Lilly and Co | 755.52B |
| Actinium Pharmaceuticals Inc | 207.82M |
| Bristol-Myers Squibb Co | 135.32B |
| Altimmune Inc | 385.90M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -21.58M |
| Total Expenses (Quarterly) | 12.00M |
| EPS Diluted (Quarterly) | -0.74 |
| Earnings Yield | -93.33% |